Amylyx Pharmaceuticals CFO James M. Frates Sells $1.21M of Stock
James M. Frates, CFO, sold 40,000 shares of Amylyx Pharmaceuticals, Inc. at $29.39 to $30.97 a share (average $30.19) in 4 transactions, worth $1.21M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 233,625 (-3.0%).
Amylyx Pharmaceuticals Co-CEO Joshua B. Cohen Sells $2.98M of Stock
Joshua B. Cohen, Co-CEO, sold 100,000 shares of Amylyx Pharmaceuticals, Inc. at $29.39 to $30.11 a share (average $29.84) in 2 transactions, worth $2.98M in total on Nov 9, 2026. Shares held after the trade: 3,513,123 (-1.7%).
Amylyx Pharmaceuticals Co-CEO Justin B. Klee Sells $2.98M of Stock
Justin B. Klee, Co-CEO, sold 100,000 shares of Amylyx Pharmaceuticals, Inc. at $29.39 to $30.11 a share (average $29.84) in 2 transactions, worth $2.98M in total on Nov 9, 2026. Shares held after the trade: 3,513,056 (-1.7%).
Amylyx Pharmaceuticals reported third quarter 2026 financial results and provided a business update, highlighting positive Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia. The company remains on track to submit a New Drug Application (NDA) by the end of 2026 and recently strengthened its balance sheet with approximately $545 million in net proceeds from a public offering.
“The third quarter was a transformational period for Amylyx, as we reported positive topline results from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia, bringing us one step closer to potentially delivering a first ever FDA-approved treatment to people living with PBH.”
Amylyx Pharmaceuticals Director George M. Milne Jr. Sells $831K of Stock
George M. Milne Jr., Director, sold 30,000 shares of Amylyx Pharmaceuticals, Inc. at $27.70 a share, worth $831K in total on Oct 5, 2026. Shares held after the trade: 782,881 (-3.7%).